Highlights
Postoperative celecoxib administration significantly reduced opioid consumption by 44% in patients undergoing benign oropharyngeal surgery. Pain scores remained comparable between celecoxib and non-celecoxib cohorts across all measured time points. These findings support the integration of celecoxib into multimodal pain management protocols to minimize opioid exposure. Larger randomized trials are needed to confirm these preliminary observations.
Background: The Opioid Challenge in Oropharyngeal Surgery
Tonsillectomy and adenoidectomy (T&A) rank among the most frequently performed surgical procedures worldwide, with uvulopalatopharyngoplasty (UPPP) serving as a key intervention for obstructive sleep apnea. Despite their clinical benefits, these procedures are associated with moderate-to-severe postoperative pain that traditionally necessitates opioid analgesia. This reliance on opioids raises significant concerns regarding side effects, dependency, and the ongoing public health crisis of opioid overprescription.
Multimodal analgesia—combining analgesics with distinct mechanisms of action—has emerged as a strategy to improve pain control while reducing opioid requirements. Nonsteroidal anti-inflammatory drugs (NSAIDs) such as celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, offer analgesic and anti-inflammatory properties without the bleeding risks associated with non-selective NSAIDs. However, evidence regarding their efficacy in oropharyngeal surgical populations remains limited.
Study Design
This retrospective cohort study enrolled patients undergoing T&A or UPPP with tonsillectomy at a single institution between May and October 2024. All participants received a standardized multimodal pain regimen consisting of acetaminophen, ibuprofen, and as-needed opioids. Patients were stratified into two cohorts based on whether celecoxib was prescribed postoperatively.
The celecoxib cohort (N=38) received 200 mg of celecoxib twice daily for five days, in addition to the standard analgesic protocol. The non-celecoxib cohort (N=42) served as a historical control group, derived from data published by Butkus et al. spanning December 2020 through January 2023. Participants completed validated surveys assessing pain scores on postoperative days (POD) 0, 1, 5, and 10. Opioid consumption was recorded in milliliters and converted to oral morphine equivalents for analysis.
Statistical analyses employed the Wilcoxon rank-sum test for continuous variables and chi-squared tests for categorical comparisons, with significance set at p<0.05. Analyses were conducted using R Studio.
Patient Characteristics
The study included 80 patients with a mean age of 33.0 years (SD=12). The cohort was predominantly female (66%) compared to male (34%), with 55% identifying as Caucasian. Baseline demographic characteristics were comparable between the celecoxib and non-celecoxib groups, supporting the validity of the historical comparison.
Key Findings: Opioid Consumption
The addition of postoperative celecoxib demonstrated a statistically significant reduction in opioid consumption. Patients in the celecoxib cohort consumed an average of 66.2 mL (SD=62.1) of opioids, compared to 118.4 mL (SD=91.6) in the non-celecoxib cohort (p=0.021). This represents a 44% reduction in opioid volume, a clinically meaningful decrease that aligns with broader efforts to minimize opioid prescribing in surgical settings.
The effect size, while notable, should be interpreted within the context of the retrospective design and relatively small sample size. Confidence intervals and further subgroup analyses were not reported in the available abstract, highlighting the need for complete publication data.
Pain Scores: No Significant Difference
Despite the substantial difference in opioid consumption, patient-reported pain scores did not differ significantly between cohorts at any measured time point. On POD 1, the mean pain score difference was not statistically significant (p=0.5). Similarly, POD 5 (p=0.2) and POD 10 (p=0.6) showed no significant differences in reported pain intensity. These findings suggest that celecoxib provided comparable analgesia to the standard regimen, potentially through its anti-inflammatory and peripheral analgesic effects.
The absence of increased pain in the celecoxib group—despite markedly lower opioid intake—supports the hypothesis that celecoxib contributes meaningfully to multimodal pain control without sacrificing patient comfort.
Safety and Tolerability
The abstract did not report adverse events or safety outcomes. This represents a notable gap, as selective COX-2 inhibitors carry theoretical risks related to cardiovascular and gastrointestinal safety, particularly in vulnerable populations. Future publications should address these considerations to guide clinical implementation.
Expert Commentary
These findings contribute valuable real-world evidence to the growing body of literature advocating for opioid-sparing analgesia in otolaryngologic surgery. The concept of multimodal pain management—combining acetaminophen, NSAIDs, and adjuncts such as gabapentinoids or dexamethasone—has gained traction across surgical disciplines, including head and neck surgery.
From a clinical perspective, the 44% reduction in opioid consumption without increased pain is compelling. In the context of the opioid crisis, even modest reductions in prescribing can translate to decreased diversion, misuse, and long-term dependency. Celecoxib’s COX-2 selectivity offers an advantage over traditional NSAIDs, particularly in procedures involving the upper airway where bleeding concerns are paramount.
However, several limitations merit consideration. The retrospective design introduces selection bias and confounding variables that cannot be fully controlled. The historical control group, while derived from a validated dataset, may reflect differences in institutional protocols, patient education, or surgical techniques over time. Furthermore, the study population was relatively young and predominantly female, limiting generalizability to older adults or males. Pain score assessment relied on patient-reported outcomes, which are inherently subjective and may be influenced by factors such as anxiety, expectation, and cultural background.
Mechanistically, celecoxib inhibits prostaglandin synthesis by selectively blocking COX-2, thereby reducing peripheral sensitization and inflammatory pain. This action complements the analgesic effects of acetaminophen and may explain why opioid reduction did not compromise overall pain control.
Conclusion
This study provides preliminary evidence that adding celecoxib to a multimodal analgesic regimen can significantly reduce opioid consumption after benign oropharyngeal surgery without compromising pain control. The findings align with current best practices emphasizing opioid minimization and suggest celecoxib as a viable adjunct in posttonsillectomy and post-UPPP pain management.
Future research should prioritize larger, randomized controlled trials to validate these observations, establish optimal dosing and duration, and comprehensively assess safety outcomes. Until then, clinicians may consider celecoxib as part of a personalized, multimodal approach—particularly for patients at elevated risk for opioid-related complications.
The broader implication of this research extends beyond individual patient care. By demonstrating that effective analgesia can be achieved with fewer opioids, studies like this reinforce the importance of deprescribing initiatives and guideline-concordant opioid stewardship across surgical specialties.
Funding and Disclosures
Funding information was not available in the provided abstract. No conflicts of interest were reported. This study was registered as an observational cohort analysis.
References
1. Platukus A, Kaki P, Kaffenes A, Tippabhatla U, Robinson J, Kim J, Creighton E, Crippen M, Boon M, Huntley C. Postoperative Effects of Celecoxib on Opioid Use and Pain Control After Benign Oropharyngeal Surgery. The Laryngoscope. 2026-03-29. PMID: 41906254.
2. Butkus et al. [Historical control data source, December 2020–January 2023]. Referenced in: Platukus et al., 2026.